No abstract available.
Fertilization in Vitro* ; Superovulation*

A retrospective study on 181 intrauterine insemination (IUI) cases using Aromatase (Al) in superovulation protocols treated in Tu Du hospital from August to December 2003. Daily doses of Anastrozole and Letrozole were 2mg and 2,5mg, respectively. All were used single or combined with FSH for superovulation. Results: Clinical pregnancy rates of cycles using Anastrozole, Letrozole, Anastrozole+FSH, and Letrozole+FSH were 18,8%, 22,8%, 26% and 29,3% respectively. Clinical pregnancy rates were not significantly different among cycles using Anastrozole and Letrozole. Stimulation duration were longer in cycles with Anastrozole than those with Letrozole. No adverse effect was recorded during the stimulation duration
Aromatase Inhibitors ; superovulation ; Insemination

No abstract available.
Estradiol* ; Female ; Menstrual Cycle* ; Superovulation*

This paper reports a case of super pregnancy in a BALB/c mouse pregnant with 30 pups following induction of superovulation using a PMSG-hCG protocol. Superovulation was induced in 10 mice by injecting 5 IU PMSG followed by 5 IU hCG 48 hours later. Immediately after injection of hCG, animals were placed with males at a ratio of 1 to 1 for 24 hours. On day 14 after mating, animals were killed by cervical dislocation and the uterus was examined for pregnancy and the number of fetuses. The mean (±SEM) number of fetuses observed in ten mice was 5.4±3.18 with an unexpectedly super pregnant mouse bearing 30 fetuses on day 14 of pregnancy.
Animals ; Dislocations ; Fetus ; Humans ; Male ; Mice* ; Pregnancy* ; Superovulation ; Uterus

No abstract available.
Chorionic Gonadotropin* ; Gonadotropin-Releasing Hormone* ; Gonadotropins* ; Humans* ; Progesterone* ; Superovulation*

No abstract available.
Follicle Stimulating Hormone* ; Gonadotropin-Releasing Hormone* ; Humans ; Superovulation*

OBJECTIVE: This study was performed to estimate the efficacy of GnRH antagonist (cetrorelix) protocol in poor responders comparing with GnRH agonist protocol. METHODS: This study included 43 cycles of 38 patients who were defined as poor responders on previous consecutive two and more superovulation cycles. The study group consisted of 20 cycles of 18 poor responders treated with cetrorelix according to single dose protocol with clomiphene citrate, who were compared with 23 cycles of 20 poor responders (control group) stimulated according to GnRH agonist flare up protocol. RESULTS: Although the use of GnRH antagonist with clomiphene citrate gave a pregnancy rate of 15% which was in the range expected for patients with poor response, the study group had higher E2 level on hCG day (1246.5 +/- 89.4 vs 644.7 +/- 34.8 pg/ml) with higher number of mature oocytes (7.8 +/- 1.3 vs 4.3 +/- 0.5), and length of stimulation (15.5 +/- 1.4 vs 19.4 +/- 2.6 days), number of hMG ampules administered (19.4 +/- 3.2 vs 45.4 +/- 5.9 ampules), and cancellation rate (35.0 vs 47.8%) were significantly lower in the cetrorelix group. Although it was not statistically significant between two groups, the pregnancy rate (15 vs 8.6%) showed higher tendency in cetrorelix group. CONCLUSION: The use of GnRH antagonist cetrorelix ended with significantly more mature oocytes, less ampules of gonadotropin, shorter duration of stimulation and lower cancellation rate in this study. So the GnRH antagonist protocol may be an alternative protocol for the treatment of poor responders.
Clomiphene ; Gonadotropin-Releasing Hormone* ; Gonadotropins ; Humans ; Oocytes ; Pregnancy Rate ; Superovulation

OBJECTIVES: To determine the effect of clomiphene/hMG combined superovulation with intrauterine insemination on pregnancy outcomes. MATERIALS AND METHODS: Eighty-one cycles of clomiphene/hMG combined superovulation with intrauterine insemination in forty-three infertile couples were analysed retrospectively. RESULTS: The overall pregnancy rate was 39.5% per patient and 20.9% per cycle. Each pregnancy rate of infertility due to ovulatory dysfunction, unexplained infertility and endometriosis was 43.8%, 40.0%, and 25.0% per patient respectively. CONCLUSIONS: Clomiphene/hMG superovulation with intrauterine insemination is a simple, cost effective and safe treatment modality in the management of infertility, and may improve a pregnancy rate.
Endometriosis ; Family Characteristics* ; Female ; Humans ; Infertility ; Insemination* ; Pregnancy ; Pregnancy Outcome ; Pregnancy Rate ; Retrospective Studies ; Superovulation*

OBJECTIVE: The objective of this study was to investigate whether serum levels of vascular endothelial growth factor (VEGF) measured at ovulation triggering day reflect ovarian response in intrauterine insemination (IUI) cycles. METHODS: Forty-nine infertile women who undergoing superovulation and IUI were included. Superovulation was performed using clomiphene citrate (100 mg/d on day 3~7) in combination with human menopausal gonadotropin (150 IU every other day starting on day 5). Serum samples were obtained on the day of hCG administration and the levels of VEGF-A and estradiol were measured. The numbers of mature follicle > or =17 mm in diameter were also counted. RESULTS: Serum VEGF-A levels did not correlate with the numbers of mature follicle count nor serum estradiol levels. Serum estradiol level was positively associated with mature follicle count. Serum VEGF-A levels tended to be lower in women with mature follicle count less than three or women with more than five. CONCLUSION: Our results indicate that serum VEGF-A levels do not have an association with superovulation outcome in IUI cycles. However, a tendency of lower VEGF-A level in poor and high responder suggests that those with extreme response to superovulation may be related with abnormal angiogenesis. Further studies should be warranted in larger populations.
Clomiphene ; Estradiol ; Female ; Gonadotropins ; Humans ; Insemination* ; Ovulation* ; Superovulation ; Vascular Endothelial Growth Factor A*

OBJECTIVE: To evaluate the efficacy of low dose gonadotropin releasing hormone agonist(GnRH-a) therapy combined with high dose human menopausal gonadotrpin(hMG) following estrogen & progesteron therapy for poor responders. METHODS: From May 1997 to Feb 1999, 36 patients who were defined as poor responders on previous consecutive two and more superovulation cycles were randomly allocated to lowdose GnRH-a short protocol with high dose hMG protocol pretreated with estrogen & progesterone(E/P therapy)(n=16)(study group) and the clomiphene citrate with hMG(n=20)(control group). All patients were planned to undergone in-vitro- fertilization(IVF) and embryo transfer(ET) after controlled ovarian hyperstimulation(COH). RESULTS: Two groups were similar with respect to clinical features and basal FSH and E2 levels. The mean level of E2 on day 5, 304.3+/-148.ng/ml in study group was significantly higher than that in control group, 182+/-34.9ng/ml. The mean levels of E2 on hCG day was also significantly higher in study group than control group(1324+/-320ng/ml, vs 414+/-168ng/ml). The mean day of hCG day in study group, 12.3+/-0.3 was shorter than that in control group, 13.8+/-0.4. The concellation rates of cycles were significantly lower in study group than control group(13.2% vs 84.2%). But clinical pregnancy rates did not showed the significant difference between two groups. CONCLUSION: The study suggested that a lowdose GnRH-a short protocol with high dose hMG pretreated with estrogen & progesterone can improve the ovarian response in poor responder group.
Clomiphene ; Embryonic Structures ; Estrogens ; Gonadotropin-Releasing Hormone* ; Humans ; Pregnancy Rate ; Progesterone ; Superovulation